The investment seeks investment results that generally correlate to the total return performance of the Prime Alternative Harvest Index... Show more
The Amplify Alternative Harvest ETF (MJ) seeks investment results that generally correspond, before fees and expenses, to the total return performance of the Prime Alternative Harvest Index. This passively managed, non-diversified fund employs a replication strategy, investing at least 80% of its net assets in index securities, including an affiliated ETF for U.S. exposure and global cannabis companies deriving at least 50% of revenue from legal cultivation, production, marketing, or distribution of cannabis or hemp products.
The fund holds 10 securities, with the top 10 comprising over 99% of assets. Key holdings include CNBS (Amplify Seymour Cannabis ETF, ~47%), TLRY (Tilray Brands, Inc., ~15%), Cronos Group Inc. (~8%), Canopy Growth Corp. (~7%), and SNDL Inc. (~6%). Sector allocations tilt heavily toward healthcare (~74%) and consumer defensive (~21%), with minor real estate and technology exposure. The portfolio is 100% small-cap focused and split roughly between U.S. (~56%) and Canada (~44%) issuers.
MJ's net expense ratio stands at 0.75%, reflecting a management fee waiver on acquired fund fees until 2027 (total gross 1.12%). The underlying index uses proprietary weighting—market cap or equal-based on cannabis engagement—and rebalances quarterly to maintain alignment with the evolving legal cannabis landscape.
The cannabis sector encompasses cultivation, production, distribution, and related products for medicinal and recreational use, driven by progressive legalization. In North America, Canada’s mature recreational market grapples with oversupply and price compression, yet exports doubled in 2025 to over 240 tonnes, targeting Germany and Australia. The U.S. features 38 states with medical programs and 24 for recreational, but federal Schedule I status imposes 280E tax burdens, curbing cash flows despite projected $47 billion revenue by 2026.
Structural growth stems from medical acceptance for chronic pain, epilepsy, and other conditions, with global medical cannabis markets expanding at 22.9% CAGR through 2034. Catalysts include President Trump’s December 2025 executive order expediting Schedule III rescheduling—potentially unlocking $1.6–2.2 billion in annual after-tax cash flow—and a looming federal ban on intoxicating hemp-derived THC by late 2026, redirecting demand to regulated channels. Risks persist from regulatory delays, litigation, international competition, and supply gluts in Canada.
In recent market cycles, MJ has exhibited heightened volatility characteristic of the cannabis sector, with year-to-date declines around 14% amid broader equity gains, reflecting ongoing price pressures and regulatory uncertainty. Over the trailing 12 months, however, the ETF delivered positive returns exceeding 17–24%, buoyed by optimism around U.S. rescheduling progress and Canadian export surges.
Recent trading sessions showed modest rebounds tied to sector rotation into thematic growth areas, as investors positioned for potential tax relief under Schedule III and reduced hemp competition. MJ’s concentrated exposure amplified reactions to earnings from top holdings like TLRY and SNDL, alongside macroeconomic factors such as stabilizing wholesale prices in Canada and global medical demand upticks.
Tickeron’s Trending AI Robots page showcases the platform’s top-performing AI trading bots under prevailing market conditions. Tickeron provides hundreds of AI bots scanning thousands of tickers across diverse strategies, timeframes, and performance metrics, from momentum and mean reversion to options trading. Only the strongest current performers—often displaying win rates above 60% and sharp risk-adjusted returns—appear in this curated section, helping investors identify adaptive tools for volatile sectors like cannabis ETFs. Explore the page to discover bots tailored to your trading style and receive actionable signals today.
Looking to 2026, the cannabis sector—and MJ by extension—stands at a policy inflection point. The Trump administration’s executive order initiates Schedule III rescheduling, potentially alleviating 280E taxes and enhancing banking access for U.S. operators, though full implementation may face litigation and extend into 2027. This could free up $1.6–2.2 billion in annual cash flows, bolstering top holdings’ balance sheets and funding expansion.
Canadian producers, comprising much of MJ’s portfolio, benefit from stabilizing wholesale prices projected at $1.41/gram amid 27% export growth, though global competition from Germany and Australia poses risks. A federal hemp-THC ban by late 2026 may curb unregulated rivals, channeling demand to licensed channels and supporting U.S.-focused CNBS. Broader trends include medical cannabis CAGR of 22.9%, rising telemedicine in Europe, and product innovation like edibles.
Monitor earnings cycles for TLRY, SNDL, and peers; quarterly index rebalancing; capital inflows post-reform clarity; and competitive pressures from peers like MSOS. MJ’s 0.75% expense ratio remains competitive, but small-cap concentration amplifies macro risks such as interest rates and commodity-like pricing dynamics. Balanced positioning favors patient investors eyeing structural legalization tailwinds.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
MJ saw its Momentum Indicator move below the 0 level on May 08, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 86 similar instances where the indicator turned negative. In of the 86 cases, the stock moved further down in the following days. The odds of a decline are at .
The 10-day RSI Indicator for MJ moved out of overbought territory on April 23, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 18 similar instances where the indicator moved out of overbought territory. In of the 18 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Moving Average Convergence Divergence Histogram (MACD) for MJ turned negative on May 08, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 41 similar instances when the indicator turned negative. In of the 41 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MJ declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
MJ broke above its upper Bollinger Band on April 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 72 cases where MJ's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
MJ moved above its 50-day moving average on April 15, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for MJ crossed bullishly above the 50-day moving average on April 20, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where MJ advanced for three days, in of 206 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 89 cases where MJ Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Category MiscellaneousSector